Merck plans to file five new drug applications this year but said it has ended development of its first stab at a follow-on biologic drug, illustrating the risks of this emerging field.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 05/11/2010 - 8:53am
Merck plans to file five new drug applications this year but said it has ended development of its first stab at a follow-on biologic drug, illustrating the risks of this emerging field.